用可诱导核糖核酶向基米拉抑制G-四重复 mRNAs用于精确瘤治疗
Yuan Zhang1, Lingyan Wang1, Fenglin Wang1
1State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, Hunan 410082, China.
Journal of the American Chemical Society
|June 4, 2024
概括
可诱导的RIBOTAC (iRIBOTAC) 能够针对癌症治疗的G四重复 (G4) RNAs进行向降解. 这种新的方法使用生物对角或细胞特异的触发器来精确地抑制G4RNA和瘤.
科学领域:
- 生物化学
- 分子生物学
- 癌症治疗
背景情况:
- 向核糖基因组 (RIBOTAC) 是一种新兴的向治疗策略.
- 通过生物对等或细胞特异性触发剂选择性激活RIBOTAC仍未研究.
研究的目的:
- 开发一种可诱导的RIBOTAC (iRIBOTAC),用于按需降解G-四重复 (G4) RNA.
- 通过控制的G4RNA沉默来实现精确的癌症治疗.
主要方法:
- 通过将近红外 (NIR) 光G4联体与非竞争性G4联体结合而设计了一种双价G4结合剂.
- 结合G4结合剂与中的核糖酶招募剂,通过生物正对应反应,瘤特异性酶或代谢物分解.
- 使用RNA测序来分析iRIBOTAC激活后的基因表达变化.
主要成果:
- 在特定的刺激下,经过iRIBOTAC介导的G4RNAs被证明是被淘汰的.
- 观察到与细胞杀死,通道调节和代谢相关的基因表达失调.
- 在小鼠模型中证实显著诱导亡和选择性瘤生长抑制.
- 通过NIR光显示选择性瘤成像能力.
结论:
- 通过启动可诱导的G4RNA向和沉默,iRIBOTAC代表了癌症治疗的一个有价值的范例.
- 该策略允许精确控制G4RNA降解,使用生物直角或瘤特异性触发剂.
- iRIBOTAC有助于选择性瘤成像和生长抑制,突出其治疗潜力.
相关概念视频
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K


